Nippon Shokubai Starts Joint Feasibility Study with PURMX on Drug Delivery Material

Nippon Shokubai has started a joint feasibility study with PURMX Therapeutics to test its folate-conjugated cationic peptide drug delivery material, Fol-Dab8, with naturally occurring microRNA for oligonucleotide therapeutics. The companies will evaluate combining Fol-Dab8 with PURMX's microRNA technology, which targets tissues with high folate receptor expression such as pancreatic cancer. Alongside the study launch, Nippon Shokubai made an equity investment in PURMX through a private placement; the amount and stake were not disclosed.

Key facts

Market context

Drug delivery materials are specialty chemicals that help therapeutic molecules reach their target cells in the body. Cationic peptides and conjugated ligands are often used to carry nucleic acid drugs such as oligonucleotides and small interfering RNA, which are otherwise broken down quickly in the bloodstream. Demand for these carriers is driven mainly by the pharmaceutical and biotechnology sectors, particularly oncology and rare disease programs, where companies seek more selective tissue targeting. Contract development and manufacturing organizations (CDMOs) benefit when such materials move into clinical development, because they supply peptide and oligonucleotide active ingredients and related development services. For chemical buyers, the main effect of a collaboration like this is on future demand patterns rather than near-term bulk supply. Pricing for pharmaceutical-grade peptides and oligonucleotides tends to reflect purity, scale and regulatory documentation, so a new application can shift order volumes and qualification work for suppliers in this niche.

Source: official release on shokubai.co.jp. Summary and context written by Market Krystal.